Phase 1Active, not recruiting
NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS
A Phase 1 Study of NKX101, an Activating Chimeric Receptor Natural Killer Cell Therapy, in Subjects With Hematological Malignancies or Dysplasias
- Sponsor
- Nkarta, Inc. (Industry)
- Enrolment
- 61 enrolled
- Conditions
- Relapsed/Refractory AML; AML, Adult; MDS; Refractory Myelodysplastic Syndromes
- Interventions
- NKX101 - CAR NK cell therapy
- Ages
- adults, older adults
- Registry
- NCT04623944
Full record on ClinicalTrials.gov
From the registry
This is a single-arm, open-label, multi-center, Phase 1 study to determine safety and tolerability of an experimental therapy called NKX101 (allogeneic CAR NK cells targeting NKG2D ligands) in patients with relapsed/refractory AML or intermediate, high and very high risk relapsed/refractory MDS.
Primary outcomes
- Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
- Response rate to NKX101 (for Part 2)
History
Study completion expected
Last registry update
Primary completion
Registered
Started